Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical and biological characteristics of patients with systemic sclerosis (SSc)

From: Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis

Characteristic Limited SSc (n = 6) Diffuse SSc (n = 6)
Raynaud's phenomenon, n 6 6
Current digital vascular ulceration, n 0 0
Lung fibrosis (computed tomography scan), n 2 4
Forced vital capacity <75%, n 0 4
DLCOc/haemoglobin <80%, n 3 3
Pulmonary hypertension (sPAP >40 mmHg), n 0 0
Positive for anti-topoisomerase I antibodies, n 0 4
Positive for anti-centromere antibodies, n 3 0
Creatinine, µmol/l (range) 73.4 ± 12.5a (56–81) 76.4 ± 13.5a (60–90)
ESR, mm/h 13.6 ± 11a 18.6 ± 15a
C-reactive protein concentration, mg/l 7.6 ± 6.1a 8.8 ± 7.4a
Low dose of prednisone (ongoing treatment), n (mean mg/day) 2 (7) 4 (7.5)
Angiotensin-converting enzyme inhibitors, n 0 3
D-Penicillamine, n 0 2
Omeprazole, n 6 6
  1. aMean ± SD.
  2. DLCOc, carbon monoxide diffusing capacity of the lung corrected for haemoglobin; ESR, erythrocyte sedimentation rate; sPAP, systolic pulmonary arterial pressure.